{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:12:13Z","timestamp":1792653133843,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11912-020-0877-0","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T21:05:01Z","timestamp":1581023101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma"],"prefix":"10.1007","volume":"22","author":[{"given":"Kyle","family":"Wierzbicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Franson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bruzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Cantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan J.","family":"Homan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard L.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed Rahman","family":"Kawakibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Teodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viveka Nand","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Koschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320. https:\/\/doi.org\/10.1007\/s00401-016-1545-1.","DOI":"10.1007\/s00401-016-1545-1"},{"key":"877_CR2","doi-asserted-by":"publisher","unstructured":"Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, et al. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology. 2018;20(1):123\u201331. https:\/\/doi.org\/10.1093\/neuonc\/nox149.","DOI":"10.1093\/neuonc\/nox149"},{"key":"877_CR3","doi-asserted-by":"publisher","unstructured":"Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425\u201337. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.024.","DOI":"10.1016\/j.ccr.2012.08.024"},{"issue":"19","key":"877_CR4","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","volume":"36","author":"LM Hoffman","year":"2018","unstructured":"Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and european society for pediatric oncology DIPG registries. J Clin Oncol. 2018;36(19):1963\u201372.","journal-title":"J Clin Oncol"},{"issue":"8","key":"877_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/neuonc\/nox021","volume":"19","author":"KJ Cohen","year":"2017","unstructured":"Cohen KJ, Jabado N, Grill J. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro-Oncology. 2017;19(8):1025\u201334. https:\/\/doi.org\/10.1093\/neuonc\/nox021.","journal-title":"Neuro-Oncology"},{"issue":"3","key":"877_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","volume":"7","author":"D Hargrave","year":"2006","unstructured":"Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241\u20138.","journal-title":"Lancet Oncol"},{"issue":"3","key":"877_CR7","doi-asserted-by":"publisher","first-page":"e1501354","DOI":"10.1126\/sciadv.1501354","volume":"2","author":"RR Lulla","year":"2016","unstructured":"Lulla RR, Saratsis AM, Hashizume R. Mutations in chromatin machinery and pediatric high-grade glioma. Sci Adv. 2016;2(3):e1501354. https:\/\/doi.org\/10.1126\/sciadv.1501354.","journal-title":"Sci Adv"},{"issue":"4","key":"877_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"\u2022 Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017;32(4):520\u201337 e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.017 This large-scale study investigated the characteristic biological and clinical differences between H3K27M-mutant and H3K27-WT DMGs, demonstrating that the histone mutation has poor prognistic implications in pediatric populations.","journal-title":"Cancer Cell"},{"issue":"6","key":"877_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00246-018-1882-z","volume":"39","author":"Y Liu","year":"2018","unstructured":"Liu Y, Chen H, Shou W. Potential common pathogenic pathways for the left ventricular noncompaction cardiomyopathy (LVNC). Pediatr Cardiol. 2018;39(6):1099\u2013106. https:\/\/doi.org\/10.1007\/s00246-018-1882-z.","journal-title":"Pediatr Cardiol"},{"key":"877_CR10","doi-asserted-by":"publisher","unstructured":"Pratt D, Natarajan SK, Banda A, Giannini C, Vats P, Koschmann C, et al. Circumscribed\/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathol. 2018;135(2):299\u2013301. https:\/\/doi.org\/10.1007\/s00401-018-1805-3.","DOI":"10.1007\/s00401-018-1805-3"},{"key":"877_CR11","doi-asserted-by":"publisher","unstructured":"Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro-Oncology. 2017;19(8):1127\u201334. https:\/\/doi.org\/10.1093\/neuonc\/now274.","DOI":"10.1093\/neuonc\/now274"},{"key":"877_CR12","doi-asserted-by":"publisher","unstructured":"Jiang H, Yang K, Ren X, Cui Y, Li M, Lei Y, et al. Diffuse midline glioma with an H3 K27M mutation: a comparison integrating the clinical, radiological, molecular features between adult and pediatric patients. Neuro-Oncology. 2019. https:\/\/doi.org\/10.1093\/neuonc\/noz152.","DOI":"10.1093\/neuonc\/noz152"},{"issue":"7","key":"877_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2176\/nmc.ra.2018-0044","volume":"58","author":"H Abe","year":"2018","unstructured":"Abe H, Natsumeda M, Kanemura Y, Watanabe J, Tsukamoto Y, Okada M, et al. MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas and MGMT silencing to temozolomide sensitivity in IDH-mutant gliomas. Neurol Med Chir (Tokyo). 2018;58(7):290\u20135. https:\/\/doi.org\/10.2176\/nmc.ra.2018-0044.","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"877_CR14","doi-asserted-by":"publisher","unstructured":"Guerra-Garcia P, Marshall LV, Cockle JV, Ramachandran PV, Saran FH, Jones C, et al. Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: a review of past, current, and emerging therapies. Pediatr Blood Cancer. 2019;e28011. doi:https:\/\/doi.org\/10.1002\/pbc.28011.","DOI":"10.1002\/pbc.28011"},{"issue":"3","key":"877_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3171\/2017.2.PEDS1665","volume":"20","author":"C Hamisch","year":"2017","unstructured":"Hamisch C, Kickingereder P, Fischer M, Simon T, Ruge MI. Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. J Neurosurg Pediatr. 2017;20(3):261\u20138. https:\/\/doi.org\/10.3171\/2017.2.PEDS1665.","journal-title":"J Neurosurg Pediatr"},{"issue":"2 Suppl","key":"877_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3171\/2017.2.PEDS1665","volume":"104","author":"DW Pincus","year":"2006","unstructured":"Pincus DW, Richter EO, Yachnis AT, Bennett J, Bhatti MT, Smith A. Brainstem stereotactic biopsy sampling in children. J Neurosurg. 2006;104(2 Suppl):108\u201314. https:\/\/doi.org\/10.3171\/2017.2.PEDS1665.","journal-title":"J Neurosurg"},{"issue":"5","key":"877_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/15592294.2016.1278095","volume":"12","author":"E Maury","year":"2017","unstructured":"Maury E, Hashizume R. Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: insight into epigenetic therapies. Epigenetics. 2017;12(5):353\u201369. https:\/\/doi.org\/10.1080\/15592294.2016.1278095.","journal-title":"Epigenetics."},{"key":"877_CR18","doi-asserted-by":"publisher","unstructured":"Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493\u2013500. https:\/\/doi.org\/10.1038\/nm.4296.","DOI":"10.1038\/nm.4296"},{"key":"877_CR19","unstructured":"Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy."},{"key":"877_CR20","unstructured":"MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Gliome (PNOC015)."},{"key":"877_CR21","doi-asserted-by":"publisher","unstructured":"Koschmann C, Farooqui Z, Kasaian K, Cao X, Zamler D, Stallard S, et al. Multi-focal sequencing of a diffuse intrinsic pontine glioma established PTEN loss as an early event. NPJ Precis Oncol. 2017;1(1):32. https:\/\/doi.org\/10.1038\/s41698-017-0033-y.","DOI":"10.1038\/s41698-017-0033-y"},{"key":"877_CR22","doi-asserted-by":"publisher","unstructured":"Salloum R, McConechy MK, Mikael LG, Fuller C, Drissi R, DeWire M, et al. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Acta Neuropathol Commun. 2017;5(1):78. https:\/\/doi.org\/10.1186\/s40478-017-0479-8.","DOI":"10.1186\/s40478-017-0479-8"},{"key":"877_CR23","doi-asserted-by":"publisher","unstructured":"Hoffman LM, DeWire M, Ryall S, Buczkowicz P, Leach J, Miles L, et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun. 2016;4:1. https:\/\/doi.org\/10.1186\/s40478-015-0269-0.","DOI":"10.1186\/s40478-015-0269-0"},{"key":"877_CR24","doi-asserted-by":"publisher","unstructured":"Filbin MG, Tirosh I, Hovestadt V, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018;360(6386):331\u20135. https:\/\/doi.org\/10.1126\/scienceaao4750.","DOI":"10.1126\/scienceaao4750"},{"issue":"6","key":"877_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm0715-827a","volume":"21","author":"CS Grasso","year":"2015","unstructured":"\u2022 Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015;21(6):555\u20139. https:\/\/doi.org\/10.1038\/nm0715-827a This study emphasizes panobinostat as a promising drug capable of partially rescuing the global hypotrimethylation of the H3K27M phenotype in vitro. Further analysis revealed synergic effects when DIPG cell cultures were treated with both panobinostat and GSK-J4.","journal-title":"Nat Med"},{"issue":"39","key":"877_CR26","doi-asserted-by":"publisher","first-page":"13498","DOI":"10.1021\/ja5060934","volume":"136","author":"ZZ Brown","year":"2014","unstructured":"Brown ZZ, M\u00fcller MM, Jain SU, Allis CD, Lewis PW, Muir TW. Strategy for \u201cdetoxification\u201d of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2. J Am Chem Soc. 2014;136(39):13498\u2013501.","journal-title":"J Am Chem Soc"},{"issue":"7","key":"877_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2176\/nmc.ra.2017-0018","volume":"57","author":"R Hashizume","year":"2017","unstructured":"Hashizume R. Epigenetic targeted therapy for diffuse intrinsic pontine glioma. Neurol Med Chir. 2017;57(7):331\u201342. https:\/\/doi.org\/10.2176\/nmc.ra.2017-0018.","journal-title":"Neurol Med Chir"},{"key":"877_CR28","doi-asserted-by":"publisher","unstructured":"Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS One. 2017;12(1):e0169485. https:\/\/doi.org\/10.1371\/journal.pone.0169485.","DOI":"10.1371\/journal.pone.0169485"},{"key":"877_CR29","doi-asserted-by":"publisher","unstructured":"Kruidenier L, Chung C, Cheng Z, Liddle J, Che K, Joberty G, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012;488(7411):404\u20138. https:\/\/doi.org\/10.1038\/nature11262.","DOI":"10.1038\/nature11262"},{"key":"877_CR30","doi-asserted-by":"publisher","unstructured":"Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014;20(12):1394\u20136. https:\/\/doi.org\/10.1038\/nm.3716.","DOI":"10.1038\/nm.3716"},{"issue":"4","key":"877_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nm.4293","volume":"3","author":"F Mohammad","year":"2017","unstructured":"Mohammad F, Weissmann S, Leblanc B, Pandey DP, Hojfeldt JW, Comet I, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 2017;3(4):483. https:\/\/doi.org\/10.1038\/nm.4293.","journal-title":"Nat Med"},{"key":"877_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128.","journal-title":"Front Immunol"},{"issue":"5","key":"877_CR33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"\u2022 Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med. 2018;24(5):572\u20139. https:\/\/doi.org\/10.1038\/s41591-018-0006-x This pre-clinical study demonstrates the efficacy and selectivity of GD2-CAR T cells in both patient-derived DIPG in vitro cell cultures and in vivo mouse models. This novel immunotherapy is promising, but its tolerability in pediatric DMG patients has yet to be demonstrated.","journal-title":"Nat Med"},{"issue":"1","key":"877_CR34","doi-asserted-by":"publisher","first-page":"ofv037","DOI":"10.1093\/ofid\/ofv037","volume":"2","author":"TA Rasmussen","year":"2015","unstructured":"Rasmussen TA, Tolstrup M, Moller HJ, Brinkmann CR, Olesen R, Erikstrup C, et al. Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. Open Forum Infect Dis. 2015;2(1):ofv037. https:\/\/doi.org\/10.1093\/ofid\/ofv037.","journal-title":"Open Forum Infect Dis"},{"key":"877_CR35","unstructured":"Trial of Panobionostat in Children With Diffuse Intrinsic Pontine Glioma (PBTC-047)."},{"key":"877_CR36","unstructured":"Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016)."},{"key":"877_CR37","unstructured":"Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma."},{"issue":"45","key":"877_CR38","doi-asserted-by":"publisher","first-page":"74380","DOI":"10.18632\/oncotarget.11814","volume":"7","author":"JE Allen","year":"2016","unstructured":"Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Onctotarget. 2016;7(45):74380\u201392. https:\/\/doi.org\/10.18632\/oncotarget.11814.","journal-title":"Onctotarget"},{"issue":"171","key":"877_CR39","doi-asserted-by":"publisher","first-page":"171ra17","DOI":"10.1126\/scitranslmed.3004828","volume":"5","author":"JE Allen","year":"2013","unstructured":"Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013;5(171):171ra17. https:\/\/doi.org\/10.1126\/scitranslmed.3004828.","journal-title":"Sci Transl Med"},{"issue":"415","key":"877_CR40","doi-asserted-by":"publisher","first-page":"ra18","DOI":"10.1126\/scisignal.aac4374","volume":"9","author":"CL Kline","year":"2016","unstructured":"Kline CL, Van den Heuvel AP, Allen JE, Prahbu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific elF2\u03b1 kinases. Sci Signal. 2016;9(415):ra18.","journal-title":"Sci Signal"},{"key":"877_CR41","unstructured":"ONC201 in Adults With Recurrent H3K27M-mutant Glioma."},{"key":"877_CR42","unstructured":"Oral ONC201 in Recurrent GBM, H3K27M Glioma, and Midline Glioma."},{"key":"877_CR43","unstructured":"ONC201 in Pediatric H3K27M Gliomas."},{"key":"877_CR44","unstructured":"Expanded Access to ONC201 for Patients With H3K27M-mutant and\/or Midline High Grade Gliomas."},{"key":"877_CR45","doi-asserted-by":"publisher","first-page":"vi81","DOI":"10.1093\/neuonc\/nox168.334","volume":"19","author":"AS Chi","year":"2017","unstructured":"Chi AS, Stafford JM, Sen N, Possemato R, Placantonakis D, Hidalgo ET, et al. H3K27M mutant gliomas are selectively killed by ONC201, a small molecule inhibitor of dopamine receptor D2. Neuro-Oncology. 2017;19:vi81. https:\/\/doi.org\/10.1093\/neuonc\/nox168.334.","journal-title":"Neuro-Oncology"},{"key":"877_CR46","unstructured":"A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma."},{"key":"877_CR47","doi-asserted-by":"publisher","unstructured":"Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, et al. Pediatric and adult H3K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neuro-Oncol. 2019;145(1):97\u2013105. https:\/\/doi.org\/10.1007\/s11060-019-03271-3.","DOI":"10.1007\/s11060-019-03271-3"},{"key":"877_CR48","doi-asserted-by":"publisher","unstructured":"Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, et al. First clinical experience with DRD2\/3 antagonist ONC201 in H3K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. J Neurosurg Pediatr. 2019:1\u20137. https:\/\/doi.org\/10.3171\/2019.2.PEDS18480.","DOI":"10.3171\/2019.2.PEDS18480"},{"key":"877_CR49","doi-asserted-by":"publisher","unstructured":"Horny\u00e1k L, Dobos N, Koncz G, Kar\u00e1nyi Z, P\u00e1ll D, Szab\u00f3 Z, et al. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. 2018;9(151). doi:https:\/\/doi.org\/10.3389\/fimmu.2018.00151.","DOI":"10.3389\/fimmu.2018.00151"},{"key":"877_CR50","doi-asserted-by":"publisher","unstructured":"Komiya T, Huang CH. Updates in the clinical development of epacadostat and other indoleamine-2,3-dioxygenase 1 inhibitors (IDO1) for human cancers. Front Oncol. 2018;8(423). doi:https:\/\/doi.org\/10.3389\/fonc.2018.00423.","DOI":"10.3389\/fonc.2018.00423"},{"issue":"Suppl 4","key":"877_CR51","doi-asserted-by":"publisher","first-page":"iv32","DOI":"10.1093\/neuonc\/nox083.131","volume":"19","author":"KL Lauing","year":"2017","unstructured":"Lauing KL, Lulla RR, Zhai L, Hashizume R, Fangusaro J, Wainwright DA. IMMU-21. Charactering IDO1 and its therapeutic potential in pediatric central nervous system tumors. Neuro-oncology. 2017;19(Suppl 4):iv32\u2013iv.","journal-title":"Neuro-oncology"},{"issue":"6","key":"877_CR52","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3171\/2015.5.JNS141901","volume":"124","author":"M Hanihara","year":"2016","unstructured":"Hanihara M, Kawataki T, Oh-Oka K, Mitsuka K, Nakao A, Kinouchi H. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model. J Neurosurg. 2016;124(6):1594\u2013601. https:\/\/doi.org\/10.3171\/2015.5.JNS141901.","journal-title":"J Neurosurg"},{"key":"877_CR53","doi-asserted-by":"publisher","unstructured":"Johnson TS, Aguilera D, Al-Basheer A, Castellino RC, Eaton BR, Esiashvili N. Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy 2018. doi:https:\/\/doi.org\/10.1158\/1538-7445.AM2018-CT004.","DOI":"10.1158\/1538-7445.AM2018-CT004"},{"key":"877_CR54","doi-asserted-by":"publisher","unstructured":"Lieberman NAP, DeGolier K, Kovar HM, Davis A, Hoglund V, Stevens J, et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro-oncology. 2019;21(1):83\u201394. https:\/\/doi.org\/10.1093\/neuonc\/noy145.","DOI":"10.1093\/neuonc\/noy145"},{"issue":"1","key":"877_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","volume":"6","author":"GL Lin","year":"2018","unstructured":"Lin GL, Nagaraja S, Filbin MG, Suva ML, Vogel H, Monje M. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2018;6(1):51. https:\/\/doi.org\/10.1186\/s40478-018-0553-x.","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"877_CR56","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.Ccr-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560\u201374. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0432.","journal-title":"Clin Cancer Res"},{"key":"877_CR57","doi-asserted-by":"publisher","unstructured":"Tang X, Zhao S, Zhang Y, Wang Y, Zhang Z, Yang M, et al. B7-H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics. 2019;14:279\u201387. https:\/\/doi.org\/10.1016\/j.omto.2019.07.002.","DOI":"10.1016\/j.omto.2019.07.002"},{"issue":"1","key":"877_CR58","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1570159X14666160614093615","volume":"15","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Singh R, Souweidane MM. Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment. Curr Neuropharmacol. 2017;15(1):116\u201328.","journal-title":"Curr Neuropharmacol"},{"key":"877_CR59","unstructured":"CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG)."},{"key":"877_CR60","doi-asserted-by":"publisher","unstructured":"Tsvankin V, Hashizume R, Katagi H, Herndon JE, Lascola C, Venkatraman TN, et al. ABC transporter inhibition plus dexamethasone enhances the efficacy of convection enhanced delivery in H3.3K27M mutant diffuse intrinsic pontine glioma. J Neurosurg. 2019. https:\/\/doi.org\/10.1093\/neuros\/nyz212.","DOI":"10.1093\/neuros\/nyz212"},{"key":"877_CR61","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1259\/bjr\/18061999","volume":"84","author":"JH Rees","year":"2011","unstructured":"Rees JH. Diagnosis and treatment in neuro-oncology: an oncological perspective. Br J Radiol. 2011;84:S82\u20139. https:\/\/doi.org\/10.1259\/bjr\/18061999.","journal-title":"Br J Radiol"},{"issue":"23","key":"877_CR62","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1158\/1078-0432.CCR-18-1345","volume":"24","author":"E Panditharatna","year":"2018","unstructured":"\u2022 Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, Gordish-Dressman H, Magge SN, et al. Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy. Clin Cancer Res. 2018;24(23):5850\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1345 This study illustrates the feasibility of liquid biopsy ctDNA quantification for therapeutic monitoring in DMG patients. ctDNA MAFs in serial CSF and plasma samples were correlated to changes in MRI tumor measurements by ddPCR analysis.","journal-title":"Clin Cancer Res"},{"key":"877_CR63","doi-asserted-by":"publisher","unstructured":"Wang Y, Springer S, Zhang M, McMahon KW, Kinde I, Dobbyn L, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112:9704\u20139. https:\/\/doi.org\/10.1073\/pnas.1511694112.","DOI":"10.1073\/pnas.1511694112"},{"key":"877_CR64","doi-asserted-by":"publisher","unstructured":"Xu R, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16:1155\u201361. https:\/\/doi.org\/10.1038\/NMAT4997.","DOI":"10.1038\/NMAT4997"},{"issue":"5","key":"877_CR65","doi-asserted-by":"publisher","first-page":"455","DOI":"10.21037\/tlcr.2016.10.07","volume":"5","author":"D P\u00e9rez-Callejo","year":"2016","unstructured":"P\u00e9rez-Callejo D, Romero A, Provencio M, Torrente M. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res. 2016;5(5):455\u201365. https:\/\/doi.org\/10.21037\/tlcr.2016.10.07.","journal-title":"Transl Lung Cancer Res"},{"key":"877_CR66","doi-asserted-by":"publisher","unstructured":"Dawson SJ, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199\u2013209. https:\/\/doi.org\/10.1056\/NEJMoa1213261.","DOI":"10.1056\/NEJMoa1213261"},{"key":"877_CR67","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40291-017-0278-8","volume":"21","author":"S Olmedillas-Lopez","year":"2017","unstructured":"Olmedillas-Lopez S, Garcia-Arranz M, Garcia-Olmo D. Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther. 2017;21:493\u2013510. https:\/\/doi.org\/10.1007\/s40291-017-0278-8.","journal-title":"Mol Diagn Ther"},{"key":"877_CR68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.radonc.2018.07.011","volume":"130","author":"C Pan","year":"2018","unstructured":"Pan C, Liu J, Tang J, Chen X, Chen F, Wu Y, et al. A machine learning-based prediction model of H3K27M mutations in brainstem gliomas using conventional MRI and clinical features. Radiother Oncol. 2018;130:172\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2018.07.011.","journal-title":"Radiother Oncol"},{"key":"877_CR69","doi-asserted-by":"publisher","unstructured":"Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, et al. Detection of histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017;5:28. https:\/\/doi.org\/10.1186\/s40478-017-0436-6.","DOI":"10.1186\/s40478-017-0436-6"},{"key":"877_CR70","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","volume":"565","author":"AM Miller","year":"2019","unstructured":"\u2022 Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019;565:654\u201370. https:\/\/doi.org\/10.1038\/s41586-019-0882-3 This study used sequencing analysis to show that the alterations found in CSF ctDNA closely mirrored those of the tumor genome. The researchers identify serial lumbar punctures as a possible diagnostic and therapeutic monitoring tool.","journal-title":"Nature"},{"key":"877_CR71","doi-asserted-by":"publisher","unstructured":"Stallard S, Savelieff MG, Wierzbicki K, Mullan B, Miklja Z, Bruzek A, et al. CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. Acta Neuropathol Commun. 2018;6:80. https:\/\/doi.org\/10.1186\/s40478-018-0580-7.","DOI":"10.1186\/s40478-018-0580-7"},{"issue":"8","key":"877_CR72","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","volume":"26","author":"J Tie","year":"2015","unstructured":"Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715\u201322. https:\/\/doi.org\/10.1093\/annonc\/mdv177.","journal-title":"Ann Oncol"},{"key":"877_CR73","doi-asserted-by":"publisher","unstructured":"Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, et al. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro-Oncology. 2019. https:\/\/doi.org\/10.1093\/neuonc\/noz022.","DOI":"10.1093\/neuonc\/noz022"}],"updated-by":[{"DOI":"10.1007\/s11912-020-00912-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000}}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0877-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-020-0877-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0877-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T02:39:53Z","timestamp":1612492793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-020-0877-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-0877-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11912-020-00912-z","asserted-by":"object"}]},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"6 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this review article unfortunately contained a mistake in the author group section.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Kyle Wierzbicki declares that he has no conflict of interest.Karthik Ravi declares that he has no conflict of interest.Andrea Franson has received both non-financial support and compensation for service as a consultant from Boehringer Ingelheim.Amy Bruzek declares that she has no conflict of interest.Evan Cantor declares that he has no conflict of interest.Micah Harris declares that he has no conflict of interest.Morgan J. Homan declares that he has no conflict of interest.Bernard L. Marini declares that he has no conflict of interest.Abed Kawakibi declares that he has no conflict of interest.Ramya Ravindran declares that she has no conflict of interest.Rodrigo Teodoro declares that he has no conflict of interest.Vivek Yadav declares that he has no conflict of interest.Carl Koschmann declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"19"}}